These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38414717)

  • 1. A Case of Type 2 Diabetes Mellitus with Lung Cancer Suffered from Euglycemic Diabetic Ketosis Accompanied by Adrenal Insufficiency after Immune Checkpoint Inhibitors.
    Shibasaki S; Noda C; Imagawa A; Sakane S
    Case Rep Endocrinol; 2024; 2024():9982174. PubMed ID: 38414717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.
    Porntharukchareon T; Tontivuthikul B; Sintawichai N; Srichomkwun P
    J Med Case Rep; 2020 Sep; 14(1):171. PubMed ID: 32988414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose co-transporter-2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report.
    Yasuma T; Okano Y; Tanaka S; Nishihama K; Eguchi K; Inoue C; Maki K; Uchida A; Uemura M; Suzuki T; D'Alessandro-Gabazza CN; Gabazza EC; Yano Y
    World J Clin Cases; 2021 May; 9(13):3163-3169. PubMed ID: 33969104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip.
    Zughaib MT; Patel K; Leka M; Affas S
    Cureus; 2022 Jan; 14(1):e21768. PubMed ID: 35251838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.
    Pfützner A; Klonoff D; Heinemann L; Ejskjaer N; Pickup J
    Endocrine; 2017 Apr; 56(1):212-216. PubMed ID: 28303514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis: A Case Report.
    Wang KM; Isom RT
    Kidney Med; 2020; 2(2):218-221. PubMed ID: 32734242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Euglycemic ketosis in an adolescent with type 1 diabetes on insulin and dapaglifozin: Case report].
    Pereyra A M; Ramírez C; Román R
    Rev Chil Pediatr; 2017 Jun; 88(3):404-410. PubMed ID: 28737202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Normal but Catastrophic" Euglycemic Diabetic Ketoacidosis Precipitated by Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.
    Sarno MJF; Hernandez DPF; Matulac MO
    Cureus; 2023 Nov; 15(11):e49236. PubMed ID: 38143642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Case of Prolonged Recovery for Post-percutaneous Coronary Intervention (PCI) Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a 28-Year-Old.
    Petersen C; Gyabaah F; Sotelo J; Yohanna S; Deoker A
    Cureus; 2023 Sep; 15(9):e45180. PubMed ID: 37842482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.
    Qiu H; Novikov A; Vallon V
    Diabetes Metab Res Rev; 2017 Jul; 33(5):. PubMed ID: 28099783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case of SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis Following Coronary Artery Bypass Surgery.
    Osafehinti DA; Okoli OJ; Karam JG
    AACE Clin Case Rep; 2021; 7(1):20-22. PubMed ID: 33851014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Euglycemic Diabetic Ketoacidosis in the Setting of SGLT2 Inhibitor Use and Hypertriglyceridemia: A Case Report and Review of Literature.
    Gajjar K; Luthra P
    Cureus; 2019 Apr; 11(4):e4384. PubMed ID: 31218148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S; Leiter A; Galsky M; Gallagher EJ
    J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
    Iesaka H; Kameda H; Miya A; Nomoto H; Cho KY; Nakamura A; Abe T; Shinohara N; Atsumi T
    Medicine (Baltimore); 2023 Dec; 102(51):e36664. PubMed ID: 38134115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
    Andrews TJ; Cox RD; Parker C; Kolb J
    J Emerg Med; 2017 Feb; 52(2):223-226. PubMed ID: 27717592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis complicating the perioperative management of a patient with type 2 diabetes mellitus (T2DM) and Fournier's gangrene: A case report.
    Lindsay PJ; Gibson LE; Bittner EA; Berg S; Chang MG
    Int J Surg Case Rep; 2020; 77():463-466. PubMed ID: 33395826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery from insulin dependence in immune checkpoint inhibitor-associated diabetes mellitus: A case report.
    Okubo M; Hataya Y; Fujimoto K; Iwakura T; Matsuoka N
    J Diabetes Investig; 2023 Jan; 14(1):147-150. PubMed ID: 36251515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SUCCESSFUL REIMPLEMENTATION OF A VERY LOW CARBOHYDRATE KETOGENIC DIET AFTER SGLT2 INHIBITOR ASSOCIATED EUGLYCEMIC DIABETIC KETOACIDOSIS.
    Fieger EI; Fadel KM; Modarres AH; Wickham EP; Wolver SE
    AACE Clin Case Rep; 2020; 6(6):e330-e333. PubMed ID: 33244496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.
    Patel K; Nair A
    Cureus; 2022 Sep; 14(9):e29652. PubMed ID: 36320965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.